Spero Therapeutics (SPRO)
(Delayed Data from NSDQ)
$1.33 USD
-0.03 (-1.85%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $1.33 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value F Growth B Momentum F VGM
Income Statements
Fiscal Year end for Spero Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 104 | 54 | 18 | 9 | 18 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 104 | 54 | 18 | 9 | 18 |
Selling & Adminstrative & Depr. & Amort Expenses | 82 | 96 | 106 | 88 | 81 |
Income After Depreciation & Amortization | 21 | -42 | -88 | -79 | -63 |
Non-Operating Income | 4 | -2 | 0 | 1 | 2 |
Interest Expense | 0 | 3 | 2 | 0 | 0 |
Pretax Income | 25 | -46 | -90 | -78 | -61 |
Income Taxes | 3 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 23 | -46 | -90 | -78 | -61 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | 23 | -46 | -90 | -78 | -61 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 22 | -41 | -87 | -78 | -62 |
Depreciation & Amortization (Cash Flow) | 0 | 1 | 1 | 1 | 1 |
Income After Depreciation & Amortization | 21 | -42 | -88 | -79 | -63 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 52.99 | 37.59 | 30.90 | 22.39 | 18.16 |
Diluted EPS Before Non-Recurring Items | 0.51 | -1.23 | -2.91 | -3.52 | -3.35 |
Diluted Net EPS (GAAP) | 0.43 | -1.23 | -2.91 | -3.52 | -3.35 |
Fiscal Year end for Spero Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 10.20 | 9.27 | 73.52 | 25.47 | 2.72 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 10.20 | 9.27 | 73.52 | 25.47 | 2.72 |
SG&A, R&D, and Dept/Amort Expenses | 29.26 | 23.25 | 22.99 | 27.40 | 15.61 |
Income After SG&A, R&D, and Dept/Amort Expenses | -19.06 | -13.98 | 50.53 | -1.93 | -12.89 |
Non-Operating Income | 1.20 | 1.31 | 1.05 | 0.94 | 0.98 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -17.86 | -12.67 | 51.58 | -0.99 | -11.91 |
Income Taxes | 0.00 | 0.00 | 0.39 | 2.21 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -17.86 | -12.67 | 51.19 | -3.21 | -11.91 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -17.86 | -12.67 | 51.19 | -3.21 | -11.91 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 53.96 | 53.52 | 53.11 | 52.71 | 52.57 |
Diluted EPS Before Non-Recurring Items | -0.33 | -0.24 | 0.96 | 0.02 | -0.23 |
Diluted Net EPS (GAAP) | -0.33 | -0.24 | 0.97 | -0.06 | -0.23 |